摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

己曲安奈德 | 5611-51-8

中文名称
己曲安奈德
中文别名
曲安西龙叔丁乙酸酯
英文名称
triamcinolone hexacetonide
英文别名
Aristospan;(11β,16α)-21-(3,3-dimethyl-1-oxobutoxy)-9-fluoro-11-hydroxy-16,17-((1-methylthylidene)bis(oxy))pregna-1,4-diene-3,20-dione;Kenalog;[2-[(1S,2S,4R,8S,9S,11S,12R,13S)-12-fluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] 3,3-dimethylbutanoate
己曲安奈德化学式
CAS
5611-51-8
化学式
C30H41FO7
mdl
——
分子量
532.65
InChiKey
TZIZWYVVGLXXFV-FLRHRWPCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    295-296° (dec); mp 271-272° (dec)
  • 比旋光度:
    D25 +90±2° (c = 1.13% in chloroform)
  • 沸点:
    619.5±55.0 °C(Predicted)
  • 密度:
    1.1277 (estimate)
  • 溶解度:
    几乎不溶于水,微溶于无水乙醇和甲醇。

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    38
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.77
  • 拓扑面积:
    99.1
  • 氢给体数:
    1
  • 氢受体数:
    8

安全信息

  • WGK Germany:
    3
  • 储存条件:
    库房应保持通风、低温和干燥。

SDS

SDS:053f13a769dd86a13fb5f8ad9b7e2b83
查看

Section 1. Chemical Product and Company Identification
Triamcinolone Hexacetonide
Common Name/
Trade Name
Triamcinolone Hexacetonide

Section 4. First Aid Measures
Eye Contact Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at
least 15 minutes. Get medical attention if irritation occurs.
Skin Contact Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops.
Serious Skin Contact Not available.
Inhalation If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get
medical attention.
Serious Inhalation Not available.
Ingestion Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an
unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight
clothing such as a collar, tie, belt or waistband.
Serious Ingestion Not available.

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Flash Points Not available.
Flammable Limits Not available.
Products of Combustion These products are carbon oxides (CO, CO2), halogenated compounds.
Fire Hazards in Presence of Slightly flammable to flammable in presence of heat.
Various Substances Non-flammable in presence of shocks.
Explosion Hazards in Presence Slightly explosive in presence of open flames and sparks.
Non-explosive in presence of shocks.
of Various Substances
SMALL FIRE: Use DRY chemical powder.
Fire Fighting Media
and Instructions LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
As with most organic solids, fire is possible at elevated temperatures
Special Remarks on
Fire Hazards
Special Remarks on Explosion Fine dust dispersed in air in sufficient concentrations, and in the presences of an ignition source is a potential dust
Hazards explosion hazard.

Section 6. Accidental Release Measures
Small Spill Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by
spreading water on the contaminated surface and dispose of according to local and regional authority
requirements.
Large Spill Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water
on the contaminated surface and allow to evacuate through the sanitary system.
Triamcinolone Hexacetonide

Section 7. Handling and Storage
Precautions Keep away from heat. Keep away from sources of ignition. Do not breathe dust.
Storage Keep container tightly closed. Keep container in a cool, well-ventilated area.

Section 8. Exposure Controls/Personal Protection
Engineering Controls Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection Safety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case of Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used
a Large Spill to avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist
BEFORE handling this product.
Exposure Limits Not available.

Section 9. Physical and Chemical Properties
Physical state and appearance Solid. (Crystalline powder.) Odor Odorless.
Taste Not available.
Molecular Weight 532.64 g/mole
White. Off-white.
Color
Not available.
pH (1% soln/water)
Boiling Point Not available.
Decomposition temperature: 295°C (563°F)
Melting Point
Critical Temperature Not available.
Specific Gravity Not available.
Vapor Pressure Not applicable.
Vapor Density Not available.
Volatility Not available.
Odor Threshold Not available.
Not available.
Water/Oil Dist. Coeff.
Ionicity (in Water) Not available.
Dispersion Properties Not available.
Solubility Insoluble in cold water, hot water.

Section 10. Stability and Reactivity Data
Stability The product is stable.
Not available.
Instability Temperature
Conditions of Instability Not available.
Incompatibility with various Not available.
substances
Corrosivity Not available.
Triamcinolone Hexacetonide
Not available.
Special Remarks on
Reactivity
Not available.
Special Remarks on
Corrosivity
Polymerization Will not occur.

Section 11. Toxicological Information
Routes of Entry Inhalation. Ingestion.
Toxicity to Animals LD50: Not available.
LC50: Not available.
Chronic Effects on Humans Not available.
Other Toxic Effects on
Slightly hazardous in case of skin contact (irritant), of ingestion, of inhalation.
Humans
Special Remarks on Not available.
Toxicity to Animals
Special Remarks on May cause adverse reproductive effects and birth defects (teratogenic) Human: passes through the placenta.
Chronic Effects on Humans
Special Remarks on other Potential Health Effects:
Toxic Effects on Humans Skin: May cause skin irritation.
Eyes: May cause eye irritation.
Inhalation: May cause respiratory tract irritaition.
Ingestion: May cause gastrointestinal tract irritation with abdominal distension, nausea, vomiting. May cause
ulcerative esophagitis and peptic ulcers. May cause fluid and electrolyte disturbances resulting in sodium
retention, fluid retention, congestive heart failure in susceptible individuals, potassium loss, hypokalemic alkalosis,
increased calcium excretion, mild diuresis, polyuria, polydypsia, hypertension. May cause depression of
appetite/anorexia in contrast to voracious appetite ordinarily encountered with other glucocorticoids. Common
corticosteroids may cause euphoria whereas Triamcinolone may cause mood depression.
May cause steroid myopathy/muscular atrophy with loss of muscle mass and muscle weakness involving
muscles of the thighs, pelvis, and low back, muscle cramps. May cause other musculoskeletal effects such as
Osteoporosis, vertebral conpression fractures, pathologic fractures of long bones. May affect immune
system/immune response and increase the susceptibly to infections. May very rarely cause hypertension,
hyperglycemia, and may affect behavior/central nervous system (excitation, vertigo, headache, convulsions,
psychosis, hallucinations), and eye problems (glaucoma, mydriasis). Dermatologic effects may include impaired
wound healing, thin fragile skin, facial erythema, petechiae and ecchymoses.

Section 12. Ecological Information
Not available.
Ecotoxicity
BOD5 and COD Not available.
Products of Biodegradation Possibly hazardous short term degradation products are not likely. However, long term degradation products may
arise.
The products of degradation are more toxic than the product itself.
Toxicity of the Products
of Biodegradation
Special Remarks on the Not available.
Products of Biodegradation
Triamcinolone Hexacetonide

Section 13. Disposal Considerations
Waste Disposal Waste must be disposed of in accordance with federal, state and local environmental
control regulations.

Section 14. Transport Information
DOT Classification Not a DOT controlled material (United States).
Not applicable.
Identification
Not applicable.
Special Provisions for
Transport
DOT (Pictograms)

Section 15. Other Regulatory Information and Pictograms
No products were found.
Federal and State
Regulations
California California prop. 65: This product contains the following ingredients for which the State of California has found
to cause cancer which would require a warning under the statute: No products were found.
Proposition 65
Warnings
California prop. 65: This product contains the following ingredients for which the State of California has found
to cause birth defects which would require a warning under the statute: No products were found.
Other Regulations EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances.
Other Classifications WHMIS (Canada) Not controlled under WHMIS (Canada).
DSCL (EEC) This product is not classified according Not applicable.
to the EU regulations.
Health Hazard
HMIS (U.S.A.) 1 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
1 0 Reactivity
Health
Reactivity
0
Specific hazard
Personal Protection
E
WHMIS (Canada)
(Pictograms)
DSCL (Europe)
(Pictograms)
TDG (Canada)
(Pictograms)
Triamcinolone Hexacetonide
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or
equivalent.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Triamcinolone hexacetonide 是一种常用的长效类固醇,具有用于亚急性和慢性炎性关节疾病研究的潜力。

体内研究

Triamcinolone hexacetonide 在化学诱导的关节软骨损伤模型中表现出显著且剂量依赖性的保护作用。接受 Triamcinolone hexacetonide 注射的小型猪显示出较少明显的纤维化和骨赘,细胞损失也更为轻微。在兔子一侧膝关节中单次注射 Triamcinolone hexacetonide 后(这些兔子曾进行部分外侧半月板切除术并断开髌下韧带和腓侧副韧带),软骨细胞克隆、细胞丢失、骨赘形成以及纤维化均有所减少。商业可用的 Triamcinolone hexacetonide 在兔眼玻璃体中的半衰期是其两倍,但前者在这一兔子模型中对视网膜有毒性作用;改革制的等渗 Triamcinolone hexacetonide 对视网膜功能和结构没有不良影响。局部应用于舌神经损伤部位,Triamcinolone hexacetonide 引起的变化可能有益,如机械敏感性的降低以及再生能力的增强。

类别

有毒物品

可燃性危险特性

可燃;燃烧会产生有毒氟化物烟雾

储运特性

库房通风、低温干燥

灭火剂

干粉、泡沫、沙土、二氧化碳、雾状水

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    醋酸曲安奈德吡啶 、 sodium hydroxide 作用下, 以 甲醇二氯甲烷 为溶剂, 生成 己曲安奈德
    参考文献:
    名称:
    [EN] NOVEL PROCESS FOR PREPARATION OF GLUCOCORTICOID STEROIDS
    [FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE STÉROÏDES DE TYPE GLUCOCORTICOÏDE
    摘要:
    本发明揭示了一种制备16,17-孕烷衍生物的16,17-缩醛的方法,其具有式(I)的结构,其中每个取代基独立地选择自; R1为H或CH3; R2为C1-C6直链或支链烷基,炔基或环烷基; 芳基或杂环芳基; 或R1和R2结合形成饱和的、不饱和的C3-C6环或杂环环; R3和R4相同或不同,每个独立地表示H或卤素; R5为-OH或-OCOR,其中R表示H或C1-C6直链、支链或环烷基,可能被取代。
    公开号:
    WO2016120891A1
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS THAT INHIBIT MCL-1 PROTEIN<br/>[FR] COMPOSÉS INHIBANT LA PROTÉINE MCL-1
    申请人:AMGEN INC
    公开号:WO2018183418A1
    公开(公告)日:2018-10-04
    Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    本文提供了髓样细胞白血病1蛋白(Mcl-1)抑制剂,其制备方法,相关的药物组合物,以及使用这些物质的方法。例如,本文提供了化合物的化学式(I)或其立体异构体;以及这些化合物的药用盐和含有这些化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。
  • [EN] DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE DIPEPTIDE ET DE TRIPEPTIDE ÉPOXY CÉTONE PROTÉASES
    申请人:ONYX THERAPEUTICS INC
    公开号:WO2014152127A1
    公开(公告)日:2014-09-25
    Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.
    本文提供了二肽和三肽环氧酮蛋白酶抑制剂,其制备方法,相关的药物组合物,以及使用它们的方法。例如,本文提供了化合物的化学式(X):及其药用盐和包括这些化合物的组合物。本文提供的化合物和组合物可以用于治疗增生性疾病,包括癌症和自身免疫疾病。
  • [EN] BORONIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDE BORONIQUE
    申请人:MERCK PATENT GMBH
    公开号:WO2016050358A1
    公开(公告)日:2016-04-07
    Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmue disorder or hematological malignancies.
    式(I)的化合物是LMP7的抑制剂,可用于治疗自身免疫性疾病或血液恶性肿瘤,等等。
  • BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
    申请人:Revolution Medicines, Inc.
    公开号:US20210139517A1
    公开(公告)日:2021-05-13
    The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    本公开涉及SOS1的调节剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。
  • [EN] COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC.<br/>[FR] COMPOSÉS (LIPOPEPTIDES À BASE DE CYSTÉINE) ET COMPOSITIONS EN TANT QU'AGONISTES DES TLR2 UTILISÉS POUR TRAITER DES INFECTIONS, INFLAMMATIONS, MALADIES RESPIRATOIRES ENTRE AUTRES
    申请人:IRM LLC
    公开号:WO2011119759A1
    公开(公告)日:2011-09-29
    The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.
    这项发明提供了一类新型化合物,即一般类似Pam3CSK4的脂肽类化合物,包括含有这类化合物的免疫原组合物和药物组合物,以及使用这类化合物治疗或预防与Toll样受体2相关的疾病或紊乱的方法。在一个方面,这些化合物可用作增强疫苗效果的佐剂。
查看更多